Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$2.66 USD
-0.09 (-3.27%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $2.66 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ESPR 2.66 -0.09(-3.27%)
Will ESPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline
Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates
Other News for ESPR
ESPR's price falls by 3.27% on September 20, though its technical setup remains stable.
Esperion’s Strategic Milestone: Nexletol Approval in Japan Boosts Financial Outlook with $120 Million Potential
ESPR: HC Wainwright & Co. Reiterates Buy Rating with $16 Target | ESPR Stock News
Esperion’s Strategic Advancements: Regulatory Approval and Market Expansion Boost
NEXLETOL Approval in Japan Boosts Esperion (ESPR) Prospects